Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Colorcon
Baxter
Mallinckrodt
AstraZeneca

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR PLAVIX


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Plavix

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00050817 ↗ Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Completed Sanofi Phase 3 2002-10-01 RATIONALE: - Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death. - In patients at risk for this disease, it is characterized by an unpredictable, sudden disruption of atherosclerotic plaques, which may lead to total occlusion of artery due to formation of a clot. The use of aspirin (blood thinner agent) for reducing those major ischemic events is either indicated, or recommended by international guidelines. However, aspirin fails to prevent a high percentage of such life-threatening events. Therefore, more effective blood thinning therapy may provide additional clinical benefit to such patients. - The results of the CURE trial in patients with unstable angina demonstrate the additional benefit of long-term treatment (up to one year) with clopidogrel, (a blood thinner agent), when administered in combination with standard therapy including aspirin. The purpose of CHARISMA is to investigate whether a similar clinical benefit of clopidogrel may apply to a broad population of high-risk patients receiving low-dose aspirin therapy. Such population includes patients with previous cardiovascular, neurovascular or peripheral arterial manifestations of atherothrombosis and patients with combinations of recognized risk factors for atherosclerosis. OBJECTIVES: - To assess the efficacy of clopidogrel 75 mg once-daily by comparison with a placebo, in preventing cardiovascular morbidity/mortality. The study will compare the efficacy of the two regimens in preventing the occurrence of major cardiovascular complications (stroke, heart attack, cardiovascular death) in high-risk patients who are otherwise receiving low-dose aspirin therapy (75-162 mg daily). - To evaluate the safety of clopidogrel in this population, and more specifically the incidence of fatal or severe bleeding (as per GUSTO definition), in order to estimate the global benefit of clopidogrel in this patient population.
NCT00140465 ↗ 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2) Completed Technische Universit√§t M√ľnchen Phase 4 2004-10-01 The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
NCT00140465 ↗ 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2) Completed Deutsches Herzzentrum Muenchen Phase 4 2004-10-01 The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
NCT00153062 ↗ PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes Completed Bayer Phase 4 2003-08-01 The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Plavix

Condition Name

Condition Name for Plavix
Intervention Trials
Coronary Artery Disease 48
Acute Coronary Syndrome 29
Myocardial Infarction 12
Healthy 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Plavix
Intervention Trials
Coronary Artery Disease 61
Coronary Disease 56
Myocardial Ischemia 53
Acute Coronary Syndrome 38
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Plavix

Trials by Country

Trials by Country for Plavix
Location Trials
United States 361
Canada 70
Korea, Republic of 41
China 40
Japan 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Plavix
Location Trials
Florida 23
Texas 18
New York 17
Ohio 17
Pennsylvania 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Plavix

Clinical Trial Phase

Clinical Trial Phase for Plavix
Clinical Trial Phase Trials
Phase 4 103
Phase 3 34
Phase 2/Phase 3 7
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Plavix
Clinical Trial Phase Trials
Completed 125
Unknown status 36
Terminated 19
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Plavix

Sponsor Name

Sponsor Name for Plavix
Sponsor Trials
AstraZeneca 15
University of Florida 9
Daiichi Sankyo Inc. 8
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Plavix
Sponsor Trials
Other 277
Industry 112
NIH 11
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Express Scripts
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.